Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke
NCT ID: NCT01518231
Last Updated: 2012-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
40 participants
INTERVENTIONAL
2012-01-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke
NCT02452502
Antiplatelet Therapy for AIS Patients With Thrombocytopenia
NCT06053021
Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
NCT05035953
Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)
NCT04590118
Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke
NCT03552354
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cell transplantation
The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.
autologous hematopoiesis stem cell transplantation
Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
Aspirin
aspirin 100mg,qd,po(patients with no fibrillation atrial)
Warfarin
warfarin 2\~6mg,qd,po(patients with fibrillation atrial);
Atorvastatin
atorvastatin 20mg,qd,po
Edaravone
edaravone 30mg,bid,ivgtt.
Convention therapy
The control group just receive drug therapy.
Aspirin
aspirin 100mg,qd,po(patients with no fibrillation atrial)
Warfarin
warfarin 2\~6mg,qd,po(patients with fibrillation atrial)
Atorvastatin
atorvastatin 20mg,qd,po
Edaravone
edaravone 30mg,bid,ivgtt
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous hematopoiesis stem cell transplantation
Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
Aspirin
aspirin 100mg,qd,po(patients with no fibrillation atrial)
Warfarin
warfarin 2\~6mg,qd,po(patients with fibrillation atrial);
Atorvastatin
atorvastatin 20mg,qd,po
Edaravone
edaravone 30mg,bid,ivgtt.
Aspirin
aspirin 100mg,qd,po(patients with no fibrillation atrial)
Warfarin
warfarin 2\~6mg,qd,po(patients with fibrillation atrial)
Atorvastatin
atorvastatin 20mg,qd,po
Edaravone
edaravone 30mg,bid,ivgtt
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no consciousness disorders
* internal carotid artery territory infarction
* stroke happened \< 1 year
* with stable hemiplegia, but remain dependent in daily life
* SSS(Scandinavian Stroke Scale) \< 40
Exclusion Criteria
* can't tolerate the test because of other disease, such as heart failure, liver failure, renal failure, abnormal blood coagulation, AIDS, combine other tumor or special condition
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang University
OTHER
Zhejiang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yaguo Li
Yaguo Li
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yaguo Li, master
Role: STUDY_DIRECTOR
Zhejiang Hospital
Yumiao Zhou, master
Role: PRINCIPAL_INVESTIGATOR
Zhejiang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yaguo Li
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Zhejiang Hospital
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.